TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Kereos, Inc.		06/12/2009	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Prolog Capital II, L.P.	
Street Address:	7733 Forsyth Blvd.	
Internal Address:	Suite 1440	
City:	St. Louis	
State/Country:	MISSOURI	
Postal Code:	63105	
Entity Type:	Type: LIMITED PARTNERSHIP: MISSOURI	

Name:	Charter Life Sciences, L.P.	
Street Address:	525 University Avenue	
Internal Address:	Suite 1400	
City:	Palo Alto	
State/Country:	CALIFORNIA	
Postal Code:	94301	
Entity Type:	LIMITED PARTNERSHIP: DELAWARE	

Name:	Memphis Biomed Ventures II, L.P.	
Street Address:	17 West Pontotoc	
Internal Address:	Suite 200	
City:	Memphis	
State/Country:	TENNESSEE	
Postal Code:	38103	
Entity Type:	LIMITED PARTNERSHIP: DELAWARE	

Name:	Triathlon Medical Ventures Fund L.P.	
Street Address:	250 East 5th Street	

0:4	1100 Chiquita Center
City:	Cincinnati
State/Country:	ОНЮ
Postal Code:	45202
Entity Type:	LIMITED PARTNERSHIP: DELAWARE
Name:	Advantage Capital Community Development Fund XV, LLC
Street Address:	7733 Forsyth Blvd.
Internal Address:	Suite 1850
City:	Clayton
State/Country:	MISSOURI
Postal Code:	63105
Entity Type:	LIMITED LIABILITY COMPANY: LOUISIANA
Name:	Alafi Capital Company, LLC
Street Address:	P.O. Box 7338
City:	Berkeley
State/Country:	CALIFORNIA
Postal Code:	94707
Entity Type:	LIMITED LIABILITY COMPANY: CALIFORNIA
Name:	Apjohn Ventures Fund, LP
Street Address:	350 E. Michigan Avenue
Internal Address:	Suite 500
City:	Kalamazoo
State/Country:	MICHIGAN
Postal Code:	48301
Entity Type:	LIMITED PARTNERSHIP: DELAWARE
Name:	Vectis Life Sciences Fund I, L.P.
Street Address:	84 State Street
City:	Boston
State/Country:	MASSACHUSETTS
Postal Code:	02109
Entity Type:	LIMITED PARTNERSHIP: DELAWARE
Name:	Samuel A. Wickline M.D.
Street Address:	11211 Pointe Court
011	St. Louis
City:	St. Louis

Postal Code:	63127
Entity Type:	INDIVIDUAL:

Name:	1998 Co-Investing LLC	
Street Address:	1034 S. Brentwood Blvd.	
Internal Address:	Suite 1860	
City:	St. Louis	
State/Country:	MISSOURI	
Postal Code:	63117	
Entity Type:	Type: LIMITED LIABILITY COMPANY: MISSOURI	

Name:	C. Aganostopoulos Revocable Trust U/A 12/21/1978
Street Address:	3959 Mount Servon Drive
City:	Bloomfield Hills
State/Country:	MICHIGAN
Postal Code:	48301
Entity Type:	TRUST: MICHIGAN

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Registration Number:	2896270	KEREOS

CORRESPONDENCE DATA

Fax Number: (314)667-3633

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 314-552-6000

Email: ipdocket@thompsoncoburn.com

Correspondent Name: Tiffany L. Schwartz
Address Line 1: One US Bank Plaza

Address Line 4: St. Louis, MISSOURI 63101

ATTORNEY DOCKET NUMBER:	44211-54099
NAME OF SUBMITTER:	Tiffany L. Schwartz
Signature:	/Tiffany L. Schwartz/
Date:	07/17/2009

Total Attachments: 16

source=SecurityAgreement#page1.tif source=SecurityAgreement#page2.tif source=SecurityAgreement#page3.tif



PATENT, TRADEMARK AND LICENSE SECURITY AGREEMENT

THIS PATENT, TRADEMARK AND LICENSE SECURITY AGREEMENT (this "Agreement") is made and entered into as of the 15th day of June, 2009, by KEREOS, INC., a Delaware corporation ("Debtor"), in favor of each of the parties identified as a secured party on Exhibit A hereto (collectively, "Secured Party").

WITNESSETH:

WHEREAS, Debtor and Secured Party are herewith entering into that certain Securities Purchase Agreement dated as of the date hereof (as the same may from time to time be amended, modified, extended, renewed or restated, the "Purchase Agreement"; all capitalized terms used and not otherwise defined in this Agreement shall have the respective meanings ascribed to them in the Purchase Agreement); and

WHEREAS, as a condition precedent to Secured Party entering into the Purchase Agreement, Secured Party has required that Debtor execute and deliver this Agreement to Secured Party; and

WHEREAS, in order to induce Secured Party to enter into the Purchase Agreement, Debtor has agreed to execute and deliver this Agreement to Secured Party; and

WHEREAS, this Agreement is being executed in connection with and in addition to the Security Agreement dated as of the date hereof and executed by Debtor in favor of Secured Party (the "Security Agreement") pursuant to which Debtor has granted to Secured Party a security interest in and lien on, among other things, all accounts, inventory, general intangibles, goods, machinery, equipment, books, records, goodwill, patents, patent applications, trademarks and trademark applications now owned or hereafter acquired by Debtor and all proceeds thereof;

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Debtor hereby covenants and agrees with Secured Party as follows:

- 1. <u>Grant of Security Interest.</u> For value received, Debtor hereby grants Secured Party a security interest in and lien on all of Debtor's right, title and interest in, to and under the following described property, whether now owned and existing or hereafter created, acquired or arising (collectively, the "<u>Collateral</u>"):
 - (a) all patents and patent applications, and the inventions and improvements described and claimed therein, including, without limitation, each patent and patent application listed on Schedules A and B, respectively, attached hereto and incorporated herein by reference (as the same may be amended pursuant hereto from time to time) and (i) the reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof, (ii) all income, damages and payments now and/or hereafter due or payable under or with respect thereto, including, without limitation, license royalties, damages and payments for past or future infringements thereof, (iii) the right to sue for past, present and future infringements thereof and (iv) all rights corresponding thereto throughout the world (all of the foregoing patents and patent applications together with the items described in clauses (i) through (iv) of this subsection (a) are hereinafter collectively referred to herein as the "Patents");
 - (b) all trademarks, service marks, trademark or service mark registrations, trade

names, trade styles, trademark or service mark applications and brand names, including, without limitation, common law rights and each mark and application listed on <u>Schedules C</u> and <u>D</u>, respectively, attached hereto and incorporated herein by reference; and (i) renewals or extensions thereof, (ii) all income, damages and payments now and/or hereafter due or payable with respect thereto, including, without limitation, license royalties, damages and payments for past or future infringements thereof, (iii) the right to sue for past, present and future infringements thereof and (iv) all rights corresponding thereto throughout the world (all of the foregoing trademarks, trade names, service marks and applications and registrations thereof together with the items described in clauses (i) through (iv) of this subsection (b) are hereinafter collectively referred to herein as the "Trademarks");

- (c) the license(s) listed on <u>Schedule E</u> attached hereto and incorporated herein by reference and all other license agreements (to the extent such license agreements may be assigned without violating the terms of any such license agreement) with respect to any of the Patents or the Trademarks or any other patent, trademark, service mark or any application or registration thereof or any other trade name or trade style between Debtor and any other Person, whether Debtor is licensor or licensee (all of the forgoing license agreements and Debtor's rights thereunder are hereinafter collectively referred to as the "<u>Licenses</u>");
- (d) the goodwill of Debtor's business connected with and symbolized by the Trademarks; and
- (e) all proceeds, including, without limitation, proceeds which constitute property of the types described in (a), (b), (c) and (d) above and any rents and profits of any of the foregoing items, whether cash or noncash, immediate or remote, and insurance proceeds, and all products of (a), (b), (c) and (d) above, and any indemnities, warranties and guaranties payable by reason of loss or damage to or otherwise with respect to any of the foregoing items;

to secure the payment of (i) any and all present and future indebtedness (principal, interest, fees, collection costs and expenses and other amounts), liabilities and obligations (including, without limitation, guaranty obligations and indemnity obligations) of Debtor under any of the Loan Documents (as such term is defined in the Security Agreement), and (ii) any and all costs of collection, legal expenses and attorneys' fees and expenses incurred by Secured Party upon the occurrence of any default or event of default under this Agreement, in collecting or enforcing payment of any such indebtedness, liabilities or obligations or in preserving, protecting or realizing on the Collateral hereunder or in representing Secured Party in connection with bankruptcy or insolvency proceedings (hereinafter collectively referred to as the "Secured Obligations").

- 2. <u>Representations, Warranties and Covenants of Debtor.</u> Debtor hereby represents and warrants to Secured Party, and covenants and agrees with Secured Party, that:
 - (a) all of the Patents, Trademarks and Licenses are subsisting and have not been adjudged invalid or unenforceable, in whole or in part, and are not at this time the subject of any challenge to their validity or enforceability;
 - (b) to the best of Debtor's knowledge, each of the Patents, Trademarks and Licenses is valid and enforceable;
 - (c) (i) no claim has been made that the use of any of the Patents, Trademarks or Licenses does or may violate the rights of any third person, (ii) no claims for patent infringement

have been commenced in connection with any of the Patents and (iii) no claims for trademark infringement have been commenced in connection with any of the Trademarks;

- (d) Except as otherwise noted herein or on any of the exhibits or schedules attached hereto, Debtor is the sole and exclusive owner of the entire and unencumbered right, title and interest in and to each of the Patents, Trademarks and Licenses, free and clear of any and all liens, charges and encumbrances, including, without limitation, any and all pledges, assignments, licenses, registered user agreements, shop rights and covenants by Debtor not to sue third persons;
- (e) Debtor has the unqualified right, power and authority to enter into this Agreement and perform its terms;
- (f) Debtor has used, and will continue to use for the duration of this Agreement, proper statutory notice in connection with its use of the registered Patents and Trademarks;
- (g) Except as otherwise noted herein or on any of the exhibits or schedules attached hereto, Debtor has the exclusive, royalty-free right and license to use the Patents, Trademarks and Licenses and agrees not to transfer any rights or interest in any of the Patents, Trademarks and/or Licenses during the term of this Agreement; and
- (h) Debtor has no notice of any suits or actions commenced or threatened with reference to any of the Patents, Trademarks and/or Licenses.
- 3. <u>Inspection Rights; Product Quality.</u> Debtor will permit inspection of Debtor's facilities which manufacture, inspect or store products sold under any of the Patents, Trademarks and/or Licenses and inspection of the products and records relating thereto by Secured Party during normal business hours and at other reasonable times. Debtor will reimburse Secured Party upon demand for all costs and expenses incurred by Secured Party in connection with any such inspection conducted by Secured Party while any Default or Event of Default under the Purchase Agreement has occurred and is continuing. A representative of Debtor may be present during any such inspection, provided that a particular representative's availability or unavailability shall not inhibit or delay such inspection. Debtor agrees to maintain the quality of any and all products in connection with which the Trademarks are used, consistent with commercially reasonable practices.
- 4. <u>Further Assurances</u>. Debtor hereby agrees that, until all of the Secured Obligations shall have been paid in full, it will not, without the prior written consent of Secured Party, enter into any agreement (for example, a license or sublicense agreement) which is inconsistent with Debtor's obligations under this Agreement or the Purchase Agreement and Debtor agrees that it will not take any action or permit any action to be taken by others subject to its control, including licensees, or fail to take any action which would affect the validity or enforcement of the rights transferred to Secured Party under this Agreement. Debtor further agrees that at any time and from time to time, at the expense of Debtor, Debtor will promptly execute and deliver to Secured Party any and all further instruments and documents and take any and all further action that Secured Party may request in good faith in order to perfect and protect the security interest granted hereby with respect to the Patents, Trademarks and Licenses or to enable Secured Party to exercise its rights and remedies under this Agreement with respect to the same.
- 5. <u>Additional Patents, Trademarks and Licenses</u>. If Debtor (a) becomes aware of any existing Patents, Trademarks or Licenses of which Debtor has not previously informed Secured Party, (b) obtains rights to any new patentable inventions, Patents, Trademarks and/or Licenses or (c) becomes

entitled to the benefit of any Patents, Trademarks and/or Licenses which benefit is not in existence on the date of this Agreement, the provisions of this Agreement shall automatically apply thereto and Debtor shall give Secured Party prompt written notice thereof.

- 6. <u>Modification by Secured Party</u>. Debtor authorizes Secured Party to modify this Agreement by amending <u>Schedules A, B, C, D</u> and/or <u>E</u> to include any future patents and patent applications, any future trademarks, service marks, trademark or service mark registrations, trade names, and trademark or service applications, and any future licenses, covered by Sections 1 and 5 hereof, without the signature of Debtor if permitted by applicable law.
- 7. <u>Use of Patents, Trademarks and Licenses</u>. So long as no Event of Default under the Purchase Agreement has occurred and is continuing, Debtor may use the Patents and Trademarks and exercise its rights under the Licenses in any lawful manner not inconsistent with this Agreement on and in connection with products sold by Debtor, for Debtor's own benefit and account and for none other.
- Default. If any Event of Default under the Purchase Agreement shall have occurred and 8. be continuing, Secured Party shall have, in addition to all other rights and remedies given it by this Agreement, those allowed by law and the rights and remedies of a secured party under the Uniform Commercial Code as enacted in any jurisdiction in which any of the Patents, Trademarks and/or Licenses may be located and, without limiting the generality of the foregoing, Secured Party may immediately, without demand of performance and without other notice (except as set forth next below) or demand whatsoever to Debtor, all of which are hereby expressly waived, and without advertisement, sell at public or private sale or otherwise realize upon, all or from time to time any of the Patents, Trademarks (together with the goodwill of Debtor associated therewith) and/or Licenses, or any interest which Debtor may have therein, and after deducting from the proceeds of sale or other disposition of the Patents, Trademarks or Licenses all expenses (including, without limitation, all expenses for brokers' fees and legal services), shall apply the residue of such proceeds toward the payment of the Secured Obligations in the order and manner as Secured Party may elect, but in any event based on each Investor's pro rata share of the Secured Obligations. Notice of any sale or other disposition of any of the Patents, Trademarks and/or Licenses shall be given to Debtor at least ten (10) business days before the time of any intended public or private sale or other disposition of such Patents, Trademarks and/or Licenses is to be made, which Debtor hereby agrees shall be reasonable notice of such sale or other disposition. At any such sale or other disposition. Secured Party or any holder of any of the Secured Obligations may, to the extent permissible under applicable law, purchase the whole or any part of the Patents, Trademarks and/or Licenses sold, free from any right of redemption on the part of Debtor, which right is hereby waived and released. Debtor agrees that upon the occurrence and continuance of any Event of Default, the use by Secured Party of the Patents, Trademarks and Licenses shall be worldwide, and without any liability for royalties or other related charges from Secured Party to Debtor. If an Event of Default shall occur and be continuing, Secured Party shall have the right, but shall in no way be obligated, to bring suit in its own name (for the benefit of itself) to enforce any and all of the Patents, Trademarks and Licenses, and, if Secured Party shall commence any such suit, Debtor shall, at the request of Secured Party, do any and all lawful acts and execute any and all proper documents required by Secured Party in aid of such enforcement and the Debtor shall promptly, upon demand, reimburse and indemnify Secured Party for all costs and expenses incurred by Secured Party in the exercise of its rights under this Agreement. All of Secured Party's rights and remedies with respect to the Patents, Trademarks and Licenses, whether established hereby, by the Security Agreement or by any other agreement or by law shall be cumulative and may be exercised singularly or concurrently.
- 9. <u>Termination of Agreement</u>. At such time as Debtor shall pay all of the Secured Obligations in full, this Agreement shall terminate and Secured Party shall execute and deliver to Debtor

all instruments as may be necessary or proper to extinguish Secured Party's security interest therein, subject to any disposition thereof which may have been made by Secured Party pursuant to this Agreement.

- 10. Expenses. Any and all fees, costs and expenses of whatever kind or nature, including, without limitation, the reasonable attorneys' fees and expenses incurred by Secured Party in connection with the preparation of this Agreement and all other documents relating hereto and the consummation of this transaction, the filing or recording of any documents (including all taxes in connection therewith) in public offices, the payment or discharge of any taxes, counsel fees, maintenance fees, encumbrances or other amounts in connection with protecting, maintaining or preserving the Patents, Trademarks and/or Licenses, or in defending or prosecuting any actions or proceedings arising out of or related to the Patents, Trademarks and/or Licenses, shall be borne and paid by Debtor on demand by Secured Party and until so paid shall be added to the principal amount of the Secured Obligations and shall bear interest at a rate per annum equal to the lesser of Eleven Percent or the highest rate of interest allowed by law from the date incurred until reimbursed by Debtor.
- 11. Preservation of Patents, Trademarks and Licenses. Debtor shall have the duty (a) to file and prosecute diligently any patent, trademark or service mark applications pending as of the date hereof or hereafter, (b) to make application on unpatented but patentable inventions and on trademarks and service marks, as commercially reasonable and (c) to preserve and maintain all rights in the Patents, Trademarks and Licenses, as commercially reasonable. Any expenses incurred in connection with Debtor's obligations under this Section 11 shall be borne by Debtor.

12. <u>Secured Party Action; Secured Party Appointed Attorney-In-Fact.</u>

- (a) The action, consent or approval of Investors holding Notes representing a majority of the aggregate principal amount represented by all Notes then outstanding shall constitute the action, consent or approval of Secured Party.
- (b) If any Event of Default under the Purchase Agreement shall have occurred and be continuing, upon ten (10) days' prior written notice to Debtor, Debtor shall be deemed to have authorized and empowered Secured Party to make, constitute and appoint any agent of Secured Party as Secured Party may select, in its sole discretion, as Debtor's true and lawful attorney-in-fact, with the power to endorse Debtor's name on all applications, documents, papers and instruments necessary for Secured Party to use the Patents, Trademarks and Licenses, or to grant or issue any exclusive or non-exclusive license under the Patents, Trademarks and Licenses to anyone else, or necessary for Secured Party to assign, pledge, convey or otherwise transfer title to or dispose of the Patents, Trademarks and Licenses to anyone else. Debtor hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney is coupled with an interest and shall be irrevocable for the duration of this Agreement.
- 13. No Waiver. No course of dealing between Debtor and Secured Party, nor any failure to exercise, nor any delay in exercising, on the part of Secured Party, any right, power or privilege under this Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege under this Agreement preclude any other or further exercise thereof or the exercise of any other right, power or privilege.
- 14. <u>Severability</u>. The provisions of this Agreement are severable, and if any clause or provision shall be held invalid and unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part thereof, in such

jurisdiction, and shall not in any manner affect such clause or provision in any other jurisdiction, or any other clause or provision of this Agreement in any jurisdiction.

- 15. <u>Amendments</u>. This Agreement is subject to amendment or modification only by a writing signed by Debtor and Secured Party, except as provided in Section 6 above.
- 16. <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, except that Debtor may not assign, transfer or delegate any of its rights, obligations or duties under this Agreement.
- 17. <u>Governing Law</u>. The validity and interpretation of this Agreement and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the substantive laws of the State of Delaware (without reference to conflict of law principles).

Signature page follows.

- 6 -

4948156.2

•	CERTIFICATE OF ACKNOWLEDGMENT
Illinois	
STATE OF MISSOURI)) SS.
Madison County) 33.

On this 12th day of June, 2009, before me personally appeared Phillip M. Buckler, to me personally known, who, being by me duly sworn, did say that he is the Vice President and General Manager of Kereos, Inc., a Delaware corporation, and that said instrument was signed on behalf of said corporation by authority of its Board of Directors; and said Phillip M. Buckler acknowledged said instrument to be the free act and deed of said corporation.

IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed my official seal in the County and State aforesaid, the day and year first above written.

(Seal) NOTARY P

OFFICIAL SEAL
NANCY K MORGAN
NOTARY PUBLIC - STATE OF ILLINOIS
MY COMMISSION EXPIRES: 10/03/11

Nancy K. Morgan Notary Public

My Commission Expires: 10/03/11

IN WITNESS WHEREOF, Debtor has executed this Agreement as of the date first written above.

DEBTOR:

KEREOS, INC.

a Delaware corporation

Phillip M. Buckler

Vice President and General Manager

EXHIBIT A

Secured Parties

Prolog Capital II, L.P.
Charter Life Sciences, L.P.
Memphis Biomed Ventures II, L.P.
Triathlon Medical Ventures Fund L.P.
Advantage Capital Community Development Fund XV, LLC
Alafi Capital Company, LLC
Apjohn Ventures Fund, LP
Vectis Life Sciences Fund I, L.P.
Samuel Wickline, M.D.
1998 Co-Investing LLC
C. Aganostopoulos Revocable Trust U/A 12/21/1978

- 9 -

4948156.2

SCHEDULE A

United States Patents

TITLE	APPLICATION # FILING DATE	PATENT # GRANT DATE
LIPOPHILIC DERIVATIVES OF CHELATE MONOAMIDES	11/146,651 6/7/2005	7,504,088 03/17/2009 Expiry: 06/07/2025
AVIDIN-BOITIN CONJUGATED EMULSIONS AS A SITE SPECIFIC BINDING SYSTEM	08/488,743 6/8/1995	5,690,907 11/25/1997 Expiry: 06/08/2015
SITE SPECIFIC BINDING SYSTEM, IMAGING COMPOSITIONS AND METHODS	09/026,216 2/19/1998	5,989,520 11/23/1999 Expiry: 05/23/2016
SITE SPECIFIC BINDING SYSTEM, IMAGING COMPOSITIONS AND METHODS	10/036,317 12/28/2001	6,821,506 11/23/2004 Expiry: 09/24/2019
METHODS FOR TARGETED DRUG DELIVERY	10/302,369 11/22/2002	7,186,399
METHOD OF MRI USING AVIDIN-BIOTIN CONJUGATED EMULSIONS AS A SITE SPECIFIC BINDING SYSTEM	08/647,277 5/23/1996	5,780,010 07/14/1998 Expiry: 06/08/2015
SITE SPECIFIC BINDING SYSTEM, IMAGING COMPOSITIONS AND METHODS	08/989,979 12/12/1997	5,958,371 09/28/1999 Expiry: 05/23/2016
SITE SPECIFIC BINDING SYSTEM, NUCLEAR IMAGING COMPOSITIONS AND METHODS	09/404,963 9/24/1999	6,548,046 04/15/2003 Expiry: 11/09/2018
LIGAND-TARGETED EMULSIONS CARRYING BIOACTIVE AGENTS	09/697,796 10/27/2000	6,676,963 01/13/2004 Expiry: 10/27/2020
ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE-CONTRAST AGENTS	09/774,278 1/30/2001	7,179,449 02/20/2007 Expiry: 01/30/2021
INTERGRIN TARGETED IMAGING AGENTS	10/351,463 1/24/2003	7,255,875 08/14/2007 Expiry: 01/24/2023
INTEGRIN TARGETED IMAGING AGENTS	11/305,416 12/16/2005	7,344,698 03/18/2008 Expiry: 01/24/2023
PARAMAGNETIC PARTICLES THAT PROVIDE IMPROVED RELAXIVITY	10/153,395 5/21/2002	6,869,591 03/22/2005 Expiry: 05/21/2022
PARAMAGNETIC PARTICLES THAT PROVIDE IMPROVED RELAXIVITY	10/400,379 3/26/2003	7,235,227 06/26/2007 Expiry: 05/21/2022

BLOOD CLOT-TARGETED NANOPARTICLES	10/225,024 8/20/2002	7,220,401
CHELATING AGENTS WITH LIPOPHILIC CARRIERS	10/765,299 1/26/2004	7,279,150 10/09/2007 Expiry: 01/26/2024

- 11 -

SCHEDULE B

United States Patent Applications

TITLE	APPLICATION # FILING DATE
NANOPARTICLE DELIVERY SYSTEMS FOR MEMBRANE-INTEGRATING PEPTIDES	12/043,063 3/5/2008
COMBINATION ANTITUMOR THERAPIES	12/160,091 1/3/2007
IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS	11/872,984 10/16/2007
ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE- DEPENDENT CONTRAST AGENTS	11/677,040 2/20/2007
INTEGRIN TARGETED IMAGING AGENTS	11/971,818 1/9/2008
BLOOD CLOT-TARGETED NANOPARTICLES	10/544,857 8/20/2003
BLOOD CLOT-TARGETED NANOPARTICLES	11/796,064 4/25/2007
CHELATING AGENTS WITH LIPOPHILIC CARRIERS	11/869,685 10/9/2007
EMULSION PARTICLES FOR IMAGING AND THERAPY AND METHODS OF USE THEREOF	10/913,846 8/6/2004
ENHANCED DRUG DELIVERY	10/993,578 11/19/2004
IMPROVED EFFICACY AND SAFETY OF TARGETED PARTICULATE AGENTS WITH DECOY SYSTEMS	10/588,572 2/10/2005
TARGETED ATHEROSCLEROSIS TREATMENT	10/492,749 1/16/2004

METHODS TO AMELIORATE AND IMAGE ANGIOPLASTY-INDUCED VASCULAR INJURY	11/607,683 12/1/2006
METHODS OF IMAGING EMPLOYING CHELATING AGENTS	11/944,271 11/21/2007
TARGETED MR IMAGING AGENTS	11/693,647 3/29/2007
DETECTION AND IMAGING OF TARGET TISSUE	11/796,415 4/27/2007
COMBINATIONS FOR TREATMENT OF NEOVASCULATURE	11/865,603 10/1/2007

- 13 -

4948156.2

SCHEDULE C

United States Trademarks

<u>Trademark No.</u> <u>Date Issued</u> <u>Description</u>

2,896,270 October 19, 2004 "KEREOS"

- 14 -

4948156.2

SCHEDULE D

United States Trademark Applications

Application No.

Date Filed

Mark

None

4948156.2

- 15 -

SCHEDULE E

Licenses

- 1. License Agreement with Barnes-Jewish Hospital as licensor and Washington University as successor dated July 13, 2001, and amended November 18, 2003 and September 10, 2004
- 2. License Agreement No. 1 with Bristol-Myers Squibb Medical Imaging, Inc. dated December 8, 2003
- 3. License Agreement No. 2 with Bristol-Myers Squibb Medical Imaging, Inc. dated December 8, 2003
- 4. License Agreement by and between Kereos, Inc. and Patrick J. Gaffney, FRC Path, D. Sc. Ph.D. dated July 7, 2004
- 5. License Agreement between the Dow Chemical Company and Kereos dated September 14, 2004
- 6. Certain license and license negotiation rights under that Research Collaboration Agreement with Genentech and Washington University dated March 5, 2008
- 7. Non-exclusive License Agreement between Kereos and The Burnham Institute dated October 10, 2005

- 16 -

4948156.2

RECORDED: 07/17/2009